Advertisement
Canada markets open in 8 hours 5 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7258
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    84.47
    +1.74 (+2.10%)
     

  • Bitcoin CAD

    85,414.70
    +393.16 (+0.46%)
     

  • CMC Crypto 200

    1,285.64
    +400.10 (+43.90%)
     

  • GOLD FUTURES

    2,397.20
    -0.80 (-0.03%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ futures

    17,365.75
    -181.50 (-1.03%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,113.53
    -966.17 (-2.54%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Company News for Dec 21, 2021

Zacks Equity Research
·1 min read

  • Intra-Cellular Therapies, Inc.’s ITCI shares rose 15.8% after the company announced that its patented Caplyta was approved by the FDA for bipolar depression.

  • Shares of Verso Corporation VRSjumped 34.9% after the company announced that it would be acquired by BillerundKorsnas for $27 per share.

  • Can-Fite BioPharma Ltd.’s CANF shares surged 69.3% after the company announced a liver cancer patient was cleared of all cancer lesions.

  • Shares of Fortuna Silver Mines Inc. FSM jumped 16.9% after the company announced the SEMARNAT granted a 12-year extension of the environmental impact authorization at the San Jose Mine.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Verso Corporation (VRS) : Free Stock Analysis Report
 
CanFite Biopharma Ltd (CANF) : Free Stock Analysis Report
 
Fortuna Silver Mines Inc. (FSM) : Free Stock Analysis Report
 
IntraCellular Therapies Inc. (ITCI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research